MSD has reported positive topline outcomes from the Phase III study of subcutaneous pembrolizumab in conjunction with ...
The phase 3 MK-3475A-D77 trial tested subcutaneous and intravenous Keytruda given every six weeks in combination with ...
Already a subscriber? Click the image to view the latest e-edition.
However, less than a quarter of patients (22.3%) had ever received treatment with pembrolizumab, and 10.7% had received lenvatinib in combination with pembrolizumab. Overall, 62.3% of patients ...
JERUSALEM, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT ®, ...
US pharma giant Merck & Co (NYSE: MRK) today announced positive top-line results from the pivotal Phase III MK-3475A-D77 ...
Investigational subcutaneous pembrolizumab and berahyaluronidase alfa, in combination with chemotherapy, demonstrates noninferior pharmacokinetics compared to intravenous KEYTRUDA in combination with ...
Merck & Co. Inc.'s reported positive results Tuesday for a new, easier-to-administer formulation of its blockbuster cancer drug Keytruda. Rahway, N.J.-based Merck (MRK) said a trial of the drug, given ...
Merck's (MRK) new injectable version of Keytruda aims to overcome regulatory hurdles and market challenges, offering a more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback